Radella Pharmaceuticals in the US has released promising Phase Ia trial results for MD-18, a novel therapy targeting PTP1B to improve glucose regulation and energy metabolism. The trial demonstrated safety, tolerability, and metabolic improvements in healthy participants, paving the way for further clinical studies.
Read MoreDid you find this insightful?
Bad
Just Okay
Amazing